Eli Lilly, Food and Drug Administration
Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with weight-loss treatment giant, Eli Lilly.
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, sparking legal and industry pushback.
Could Weight-Loss Drugs Help Get People Back to Work? The U.K. Wants to Find Out.
The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.
Britain to study use of Lilly's weight loss drug to get people back to work
Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy. Health minister Wes Streeting predicted the use of the drug - a competitor to Novo Nordisk's Ozempic - could help transform the health of the nation,
How will weight loss drug trial for unemployed work?
A study on the "real-world" effectiveness of weight loss drugs is set to measure the impact on the job prospects of people living with obesity in Greater Manchester. The five-year clinical trial was announced as part of a £279m plans by US pharmaceutical giant Eli Lilly to work with the UK government to address public health challenges like obesity.
UK plans weight loss drug trials to get people back to work
The UK plans to test US firm Eli Lilly' s weight loss jab Mounjaro to help the burden on the national healthcare system. Over a quarter of UK adults suffered from obesity in 2023 according to government data.
Unemployed obese people to be given weight loss jabs to help them 'get back to work'
Health Secretary Wes Streeting said "widening waistbands" were placing a burden on the NHS and Ozempic or Mounjaro could be administered
How Eli Lilly Outpaces Nvidia—Here Is One Chart
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
FiercePharma1d
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
Eli Lilly: A Strong Buy on Robust Revenue Growth and Expanding Market Potential
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.
FiercePharma12d
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...